Malignant T-cell lymphocyte

Malignant T-cell lymphocyte" does not refer to a specific molecule, receptor, or protein, but rather to a population of cancerous T lymphocytes found in T-cell lymphomas, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). These malignant lymphocytes are characterized by clonal expansion, acquisition of oncogenic mutations, alterations in phenotype (memory, effector, or helper subtypes), and varied interaction with the tumor microenvironment[1][4][2][5][3]. Different molecular subtypes exist (such as TH2-biased, GATA3-high, TBX21-high, or central-memory-like) and have clinical, biological, and prognostic implications[4][2][3]. Modern classification of T-cell lymphomas relies on pathology, immunophenotyping, genetic abnormalities, and gene expression profiles rather than a single aberrant molecule[5][3][6]. Thus, "malignant T-cell lymphocyte" is not suitable as a canonical molecular target. Key clarification: - The term is **not a molecular target**, receptor, or druggable molecule. It is a description of **malignant cell populations** with highly heterogeneous molecular drivers across distinct lymphoma subtypes[1][2][3][5]. - **Therapeutic strategies** are directed at markers (e.g., CD4, CD7, CCR4), signaling pathways (e.g., STAT3, MYC, RHOA), or transcription factors (e.g., GATA3, TBX21), not at "malignant T-cell lymphocyte" generically[4][2][6].

Other names

Cutaneous T-cell lymphoma cellPeripheral T-cell lymphoma cellMalignant T lymphocytePTCL cellCTCL cell